Surgerii Robotics has launched the SMRAT multicenter randomized controlled trial (RCT), in partnership with top Chinese institutions including Ruijin Hospital, Shandong Provincial Hospital, and others. This landmark study compares single-port and multi-port robotic-assisted total mesorectal excision (TME) for rectal cancer—aiming to establish new clinical standards for ultra-minimally invasive surgery.
Powered by Surgerii’s proprietary snake-arm technology, the SHURUI® single-port surgical robot enables precise dissection and reconstruction through a single incision. The trial will evaluate key outcomes such as safety, recovery speed, oncological effectiveness, and patient quality of life.
SMRAT marks a milestone in evidence-based innovation. It also supports future inclusion in guidelines, national reimbursement, and international adoption.
Surgerii Robotics is advancing from innovation to leadership—bringing next-generation surgical solutions to patients worldwide.
Important Notes
The Single-port Endoscopic Surgical System (SR-ENS-600), developed and produced by Beijing Surgerii Robotics Company Limited, has been approved by the National Medical Products Administration (NMPA) in China for urology and gynecology laparoscopic surgeries. Surgeons who wish to learn the surgical operations of the SHURUI robot should contact Beijing Surgerii Robotics Co., Ltd. to participate in the official training program. Patients who want to participate in the registered clinical trials of the SHURUI robot should contact the official cooperative hospitals of Surgerii and consult with surgeons to determine their suitability for surgery with the SHURUI robot. Both surgeons and patients should carefully understand all information regarding the performance of surgeries by the SHURUI robot and its potential risks.
Beijing Surgerii Robotics Co., Ltd. owns Surgerii®, SHURUI®, and other
trademarks and may not be used without permission.
